Pfizer Reports Nearly $37 Billion in COVID-19 Vaccine Sales Last Year

But earnings guidance for 2022 below analysts' forecasts

A medical syringe and vials of the Pfizer U.S. pharmaceutical corporation and BioNTech German biotechnology company logos are seen in New York City on Oct. 3, 2021. Cindy Ord/Getty Images for Pfizer/BioNTech

Pfizer’s COVID-19 vaccine brought in a bumper income of nearly $37 billion in sales for 2021, the product’s first full year on the market, though Pfizer’s revenue forecasts for 2022 came in below analysts’ expectations, sending its shares down by over 5 percent.

Called Comirnaty, the company’s two-dose COVID-19 vaccine generated $36.78 billion in revenue for 2021, Pfizer said in its latest quarterly earnings report released Feb. 8 (pdf).